You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1798 Results
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Jul 2021
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Aug 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2021
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma
Mar 2023
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Sep 2023

Pages